England without Atkinson but regains Carse and Woakes for first test against India
England's remodeled pace attack lost Gus Atkinson to injury but has regained Chris Woakes and Brydon Carse for the first test against India starting on June 20 in Leeds.
With Atkinson ruled out of selection after injuring his right hamstring in the innings defeat of Zimbabwe in last month's one-off test, England again has had to shuffle a fast-bowler unit missing injured pair Mark Wood (knee) and Jofra Archer (thumb) and permanently deprived of now-retired stalwarts James Anderson and Stuart Broad.
Woakes has only recently returned from a long-term ankle injury and has been playing for England's second-string Lions against India A. Carse also missed the match against Zimbabwe while he fully recovered from a toe injury sustained while playing in the Champions Trophy in February, but is set to return.
Meanwhile, Jamie Overton, a bowling allrounder, has been picked despite breaking his right little finger during a one-day international against the West Indies on May 29 and is back in the test squad for the first time since June 2022 when he earned his sole cap against New Zealand.
That was at Headingley, where England and India will begin their highly anticipated five-match series.
Also in the 14-man squad is rising star batter Jacob Bethell, who didn't return home from the Indian Premier League to play against Zimbabwe but has been playing in the ODIs against the Windies.
It looks to be a straight shootout between Bethell and Ollie Pope to bat at No. 3, but Pope has the edge given he is vice captain and scored a big century against the Zimbabweans.
There will be further tests at Edgbaston, Lord's, Old Trafford and the Oval.
___
England squad: Ben Stokes (captain), Shoaib Bashir, Jacob Bethell, Harry Brook, Brydon Carse, Sam Cook, Zak Crawley, Ben Duckett, Jamie Overton, Ollie Pope, Joe Root, Jamie Smith, Josh Tongue, Chris Woakes.
___
AP cricket: https://apnews.com/hub/cricket
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Florian Wirtz joins list of most expensive soccer signings in history
Florian Wirtz became one of the most expensive players in soccer history when the Germany playmaker joined Liverpool from Bayer Leverkusen on Friday for a fee of up to 116 million pounds ($156 million). Neymar: $262 million (222 million euros) Advertisement Paris Saint-Germain shattered the world-record transfer fee by signing the Brazil superstar from Barcelona in August 2017. It was more than double the outlay of Manchester United to sign Paul Pogba from Juventus for $116 million a year earlier. It remains the record transfer fee. ___ Kylian Mbappé: $216 million (180 million euros) A few weeks after buying Neymar, PSG also secured a loan deal for Mbappé — then the rising star of French soccer playing for Monaco — that included the option to make the move permanent in 2018. PSG did so, making it an outlay of nearly $500 million on two players. ___ Philippe Coutinho: $192 million (160 million euros) Advertisement Flush with cash after selling Neymar a year earlier, Barcelona spent most of it in a deal to buy Brazil playmaker Coutinho from Liverpool for a Spanish record fee. ___ Moises Caicedo: $146 million (115 million pounds) The Ecuador midfielder's move was previously the most expensive deal by a British club, with Chelsea buying him from Brighton in August 2023. ___ João Félix: $140 million (126 million euros) Atletico Madrid triggered a buyout clause in Félix's contract to sign the Portugal forward from Benfica in August 2019. ___ Jude Bellingham: $139 million (128.5 million euros) The England star got his big move to Real Madrid from Borussia Dortmund in June 2023, for an initial up-front fee of 103 million euros plus add-ons linked to performance. Advertisement ___ Antoine Griezmann: $134 million (120 million euros) Atletico could afford to sign Félix after selling France forward Griezmann to Barcelona for a similar fee a few weeks earlier. ___ Neymar: $98 million (90 million euros) Outside from Europe, the biggest transfer deal also involved Neymar when he joined Al Hilal, a team in the Saudi Pro League, from Paris Saint-Germain in August 2023. That came at the height of Saudi Arabia's push to sign high-end soccer talent to ignite the oil-rich state's domestic league. ___ AP soccer: Steve Douglas, The Associated Press
Yahoo
2 hours ago
- Yahoo
Potential record deal puts Elliott's name back in the headlines as Albion are linked
Harvey Elliott, pictured with Yasin Ayari, could be on the move (Image: Simon Dack) Harvey Elliott's name is being linked with Albion again – after Liverpool clinched a record deal. The champions' move for Florian Wirtz will set them back an initial £100 million. That will become a British record £116 million if various clauses are met. Advertisement It also appears to affect Elliott's potential to play significant minutes for the Reds. Albion were believed to be interested in Elliott during the January transfer window and probably before that. That might at least partly explain why The Sun report him to be of interest to the Seagulls in the current window. He would command a sizeable fee and comes with some uncertainty over what he can produce in the Premier League on a consistent basis. But Elliott, who is currently with England under-21s at the Euros, has shown plenty of promise. He scored for Liverpool at the Amex towards the end of the season. Advertisement There is no suggestion that Albion have bid for Elliott but there is a theory the presence of his former Anfield mentor James Milner could help persuade the 22-year-old to move. Albion have an array of options in attacking midfield areas but plenty of outward activity is expected during the summer transfer window.
Yahoo
2 hours ago
- Yahoo
Weight loss pill shows promise in new trial
A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
